Celestial Insights: Unraveling the Role of MiR-3682-3p in Hepatocellular Carcinoma

Overview

Journal Clin Transl Gastroenterol

Specialty Gastroenterology

Date 2024 Feb 9

PMID 38334941

Authors

Pei-Dong Miao

Ying Li

Yu-Dong Jiang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) remains a formidable oncological challenge, calling for innovative therapeutic strategies to improve patient outcomes. MicroRNAs have emerged as key regulators in cancer, and miR-3682-3p shows potential as a diagnostic and prognostic biomarker in HCC. We conducted a comprehensive study to uncover its role in HCC biology, revealing dysregulation and clinical associations. Target gene analysis provided insights into potential molecular mechanisms. Moreover, we explored its impact on the tumor microenvironment, immune cell infiltration, and therapy responses. Our findings highlight miR-3682-3p as a promising candidate for further investigations and potential therapeutic strategies in HCC management.

References

Liu S, Wen Y, Quan B, Lin J, Zhu Z, Tang J . [High expression of miR-3682-3p is an unfavorable prognostic factor of hepatocellular carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao. 2022; 41(12):1885-1891. PMC: 8752420. DOI: 10.12122/j.issn.1673-4254.2021.12.19. View

Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

Chen Q, Yang S, Zhang Y, Han S, Jia L, Li B . miR-3682-3p directly targets FOXO3 and stimulates tumor stemness in hepatocellular carcinoma a positive feedback loop involving FOXO3/PI3K/AKT/c-Myc. World J Stem Cells. 2022; 14(7):539-555. PMC: 9350627. DOI: 10.4252/wjsc.v14.i7.539. View

Farhan M, Wang H, Gaur U, Little P, Xu J, Zheng W . FOXO Signaling Pathways as Therapeutic Targets in Cancer. Int J Biol Sci. 2017; 13(7):815-827. PMC: 5555100. DOI: 10.7150/ijbs.20052. View

Morla S . Glycosaminoglycans and Glycosaminoglycan Mimetics in Cancer and Inflammation. Int J Mol Sci. 2019; 20(8). PMC: 6514582. DOI: 10.3390/ijms20081963. View

McGeary S, Lin K, Shi C, Pham T, Bisaria N, Kelley G . The biochemical basis of microRNA targeting efficacy. Science. 2019; 366(6472). PMC: 7051167. DOI: 10.1126/science.aav1741. View

Di Leva G, Garofalo M, Croce C . MicroRNAs in cancer. Annu Rev Pathol. 2013; 9:287-314. PMC: 4009396. DOI: 10.1146/annurev-pathol-012513-104715. View

Garofalo M, Quintavalle C, Romano G, Croce C, Condorelli G . miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2011; 12(1):27-33. PMC: 3673714. DOI: 10.2174/156652412798376170. View

10.

Wang X, Wang Q . Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity. Can J Gastroenterol Hepatol. 2018; 2018:9049252. PMC: 5899840. DOI: 10.1155/2018/9049252. View

11.

Ma C, Deenick E . Human T follicular helper (Tfh) cells and disease. Immunol Cell Biol. 2013; 92(1):64-71. DOI: 10.1038/icb.2013.55. View

12.

Hada M, Edin M, Hartge P, Lih F, Wentzensen N, Zeldin D . Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2018; 28(1):189-197. PMC: 6325018. DOI: 10.1158/1055-9965.EPI-18-0392. View

13.

Emmenegger U, Kerbel R . Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Onkologie. 2007; 30(12):606-8. DOI: 10.1159/000111479. View

14.

Zhou W, Guo S, Liu M, Burow M, Wang G . Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Curr Med Chem. 2017; 26(17):3026-3041. PMC: 5949083. DOI: 10.2174/0929867324666170830111531. View

15.

Jia Y, Zeng Z, Li Y, Li Z, Jin L, Zhang Z . Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression. PLoS One. 2015; 10(2):e0117458. PMC: 4331507. DOI: 10.1371/journal.pone.0117458. View

16.

Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouze E, Blanc J . Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017; 67(4):727-738. DOI: 10.1016/j.jhep.2017.05.014. View

17.

Granito A, Marinelli S, Terzi E, Piscaglia F, Renzulli M, Venerandi L . Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Dig Liver Dis. 2015; 47(6):518-22. DOI: 10.1016/j.dld.2015.03.010. View

18.

Senzolo M, Garcia-Tsao G, Garcia-Pagan J . Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol. 2021; 75(2):442-453. DOI: 10.1016/j.jhep.2021.04.029. View

19.

Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C . MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst. 2010; 102(10):706-21. PMC: 2873185. DOI: 10.1093/jnci/djq102. View

20.

Vinuesa C, Linterman M, Yu D, MacLennan I . Follicular Helper T Cells. Annu Rev Immunol. 2016; 34:335-68. DOI: 10.1146/annurev-immunol-041015-055605. View